Perry Oscar, Ellis Robert, Dang Sanjana, John George T, Hendry Stephanie, Ng Monica Suet Ying
Kidney Health Service, Royal Brisbane and Women's Hospital, Herston, Australia.
Faculty of Medicine, University of Queensland, Herston, Australia.
Nephrology (Carlton). 2025 Jul;30(7):e70066. doi: 10.1111/nep.70066.
Parvovirus B19 infection can rarely manifest with pure red cell aplasia in immunocompromised hosts. This case details a 48-year-old male, 11 years post kidney-pancreas transplant who was admitted with a chronic normocytic anaemia (haemoglobin 72 g/L) after being admitted four months prior with a bleeding peptic ulcer, requiring eight units of packed red blood cells. In the following months, the recipient required eight further packed red blood cell units despite normal repeat upper and lower gastrointestinal endoscopies. He had normal haematinics, with a persistent reticulocytopenia (0.3%, 7 × 10 cells/L) despite 80 μg per week of subcutaneous darbepoetin alfa. Platelet and leukocyte counts were within normal limits. Parvovirus B19 polymerase chain reaction (PCR) test result was "detected" with a low cycle threshold (Ct) value of 13 generated by real-time PCR (RT-PCR). Transfusion-transmitted parvovirus was considered due to temporal association with recent blood products, but retrospective testing demonstrated that parvovirus serology and PCR results were "not detected" pre-transfusion; and that the first "detected" PCR result occurred following the first packed red blood cell transfusion. Australian Red Cross Lifeblood was notified, and lookback investigations excluded the blood products as a route for parvovirus transmission, postulating that community acquisition was most likely. High dose intravenous immunoglobulin (IVIG total 400 mg/kg/day over 5 days) and immunosuppression reduction led to haemoglobin stability to > 80 g/L over 14 days. Treatment response was further extrapolated by a parvovirus PCR cycle threshold increase to 25, 7 days after first IVIG dose in the absence of gold standard quantitative PCR testing unavailability.
细小病毒B19感染在免疫功能低下的宿主中很少表现为纯红细胞再生障碍。本病例详细介绍了一名48岁男性,在肾胰联合移植11年后,因4个月前因消化性溃疡出血入院,当时接受了8单位的浓缩红细胞输血,此次因慢性正细胞性贫血(血红蛋白72g/L)再次入院。在接下来的几个月里,尽管重复进行的上、下消化道内镜检查结果正常,但受者仍需要另外8单位的浓缩红细胞。他的造血因子正常,尽管每周皮下注射80μg的达贝泊汀α,但持续性网织红细胞减少(0.3%,7×10⁹/L)。血小板和白细胞计数在正常范围内。细小病毒B19聚合酶链反应(PCR)检测结果为“检测到”,实时PCR(RT-PCR)产生的低循环阈值(Ct)值为13。由于与近期血液制品存在时间关联,曾考虑输血传播的细小病毒,但回顾性检测表明,输血前细小病毒血清学和PCR结果均为“未检测到”;首次“检测到”的PCR结果发生在首次输注浓缩红细胞之后。已通知澳大利亚红十字会血液中心,回顾性调查排除了血液制品作为细小病毒传播途径的可能性,推测最有可能是社区感染。高剂量静脉注射免疫球蛋白(5天内总量为400mg/kg/天)和减少免疫抑制导致血红蛋白在14天内稳定在>80g/L。在无法进行金标准定量PCR检测的情况下,首次静脉注射免疫球蛋白剂量7天后,细小病毒PCR循环阈值升至25,进一步推断了治疗反应。